Vascepa is a prescription medication used to reduce the risk of cardiovascular events in people with high triglyceride levels. It contains the active ingredient eicosapentaenoic acid (EPA), which is an omega-3 fatty acid. According to DrugPatentWatch [1], the patent for Vascepa expired in 2020, which means that generic versions of the drug are now available on the market.

One of the generic versions of Vascepa is called Epanova, which is produced by AstraZeneca. However, in 2019, AstraZeneca announced that it would no longer pursue the development of Epanova due to disappointing clinical trial results [2]. Therefore, it is unclear whether Epanova will be available as a generic alternative to Vascepa.

Another generic version of Vascepa is called Lovaza, which contains a different active ingredient called omega-3-acid ethyl esters. According to SingleCare [3], Lovaza is generally less expensive than Vascepa, with an average retail price of $330 for a 30-day supply compared to $370 for Vascepa. However, it is important to note that the cost of these medications may vary depending on factors such as insurance coverage and pharmacy location.

In conclusion, while the generic version of Vascepa called Epanova may not be available due to its discontinuation, Lovaza is a similar medication that may be a less expensive alternative to Vascepa. It is important to consult with a healthcare provider and insurance provider to determine the most appropriate and cost-effective treatment option.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.formularywatch.com/view/prime-therapeutics-two-drugs-from-medicare-formularies
[3] https://www.singlecare.com/blog/vascepa-vs-lovaza/